Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause

@article{Wurz2014SafetyAE,
  title={Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause},
  author={Gregory T. Wurz and Chiao-Jung Kao and Michael W. Degregorio},
  journal={Clinical Interventions in Aging},
  year={2014},
  volume={9},
  pages={1939 - 1950}
}
During the menopausal transition, women experience a number of symptoms due to declining estrogen levels, including vasomotor symptoms and vulvar and vaginal atrophy (VVA). Unlike vasomotor symptoms, vaginal dryness and dyspareunia, the main symptoms of VVA, typically worsen without treatment and can significantly impact the quality of life. Up to 60% of postmenopausal women may be affected by VVA, but many women unfortunately do not seek treatment due to embarrassment or other factors. After… 

Figures and Tables from this paper

The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause.
TLDR
For postmenopausal women with at least one VVA symptom, the presence of physician-confirmed VVA is associated with significant impaired sexual function, as shown by unadjusted analyses.
Vulvovaginal atrophy of menopause and its impact on sexual function in an Italian clinical cohort of post-menopausal women
TLDR
It is demonstrated that inquiring about VVA using a structured questionnaire may increase the diagnosis of VVA related changes in sexual function, and an impairment of sexual function is significantly associated with VVA diagnosis in Italian postmenopausal women.
Genitourinary syndrome of menopause: Current and emerging therapies With more than 1 billion menopausal women likely to be affected by vulvovaginal atrophy worldwide by 2025, the need for effective remedies is acute. Here, 3 experts survey the options.
TLDR
The therapies available for Genitourinary syndrome of menopause are surveyed, focusing first on proven treatments such as local estrogen administration and use of ospemifene (Osphena), and then describing an emerging treatment involving the use of fractional CO 2 laser.
Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?
TLDR
The worsening of QoL in patients due to symptoms related to GSM can lead to discontinuation of hormone adjuvant therapies and therefore must be addressed properly, according to health care professionals.
Safety of Ospemifene during Real-Life Use
TLDR
The development programme for ospemifene was based on the FDA Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Recommendations for Clinical Evaluation and the EMA Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women.
Randomized, Double-Blind, Placebo-Controlled Study of Modified Erzhi Granules in the Treatment of Menopause-Related Vulvovaginal Atrophy
TLDR
MEG significantly alleviates menopause-related vulvovaginal atrophy, with no overt adverse effects on the endometrium, breast, hepatic, and renal functions.
Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes
TLDR
Based on study data up to 1 year, the fractional CO2 laser may be an effective and safe treatment for women suffering from symptoms of GSM, although additional studies with larger populations and placebo control is needed to confirm these results.
Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study
TLDR
Ospemifene seems to be effective in decreasing the VVA symptoms in CC survivors and a significant improvement of each parameter of VHI has been demonstrated.
...
1
2
3
...

References

SHOWING 1-10 OF 56 REFERENCES
Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy
TLDR
In this study, once-daily oral ospemifene 60 mg was effective for the treatment of vulvar and vaginal atrophy in postmenopausal women with dyspareunia.
Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study
TLDR
Ospemifene was shown to be effective and well tolerated for the treatment of the symptoms of vaginal dryness and dyspareunia associated with vulvovaginal atrophy over and above the use of provided lubricants.
Ospemifene, vulvovaginal atrophy, and breast cancer.
Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause
  • R. Nappi, S. Palacios
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2014
TLDR
It is essential to overcome the vaginal ‘taboo’ in order to optimize elderly women's health care and include VVA in the menopause agenda, by encouraging an open and sensible conversation on the topic of intimacy and performing a gynecological pelvic examination.
Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial
TLDR
Ospemifene at daily doses of 30 to 90 mg did not stimulate endometrium or aggravate hot flashes but clearly had a rather strong estrogenic effect on the vaginal epithelium during a 3-month treatment period, as evidenced by an increase in intermediate and superficial cells in repeat Pap smears.
Prevalence and impact of vaginal symptoms among postmenopausal women.
TLDR
The prevalence and perceived severity of VVA symptoms were substantial but less frequent in nonsexually active women and analysis of MHT use by past or current hormone use indicated a trend away from oral dosing and towards patch or vaginal hormones.
Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview
TLDR
The role, safety and effectiveness of topical vaginal estrogen therapy are provided, which reverse atrophic changes and relieve associated symptoms, while avoiding systemic effects.
Vulvovaginal atrophy.
TLDR
Clinical findings include the presence of pale and dry vulvovaginal mucosa with petechiae, and the cervix may become flush with the vaginal wall, which supports the diagnosis of VVA.
...
1
2
3
4
5
...